Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

Saved in:
Bibliographic Details
Published inLeukemia Vol. 32; no. 2; pp. 562 - 565
Main Authors Topp, M S, Stelljes, M, Zugmaier, G, Barnette, P, Heffner, L T, Trippett, T, Duell, J, Bargou, R C, Holland, C, Benjamin, J E, Klinger, M, Litzow, M R
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.02.2018
Nature Publishing Group
Subjects
692/699/1541/1990/283/2125
692/700/565/251
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Blinatumomab
Cancer Research
Care and treatment
Critical Care Medicine
Development and progression
Hematology
Intensive
Internal Medicine
Letter to the Editor
Leukemia
Lymphatic leukemia
Medicine
Medicine & Public Health
Monoclonal antibodies
Oncology
Patient outcomes
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
Former Amgen employee.
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2017.306